Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Open in API
Filings indexed 950 across all filing types
Latest filing 2025-08-12 Director's Dealing
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-08-12 English
8-K
Legal Proceedings Report Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes that are important to shareholders. The content describes the dismissal of a legal claim against the company and its board, detailing the lawsuit, amendments to bylaws, and settlement of fees. There are no financial statements or detailed financial data presented. The primary focus is on a legal proceeding update. Therefore, this document fits best under the category of Legal Proceedings Report (LTR). The document length is 4060 characters, which is typical for an 8-K filing reporting a specific event rather than a full financial report.
2025-08-01 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the appointment of a new Senior Vice President and Chief Financial Officer, detailing the employment agreement and background of the new executive. This is a clear announcement of a change in senior management. There are no financial statements or detailed financial performance data included, so it is not an Annual Report, Interim Report, or Earnings Release. The primary subject is the management change, fitting the Board/Management Information category.
2025-07-21 English
Director's Dealing 2025
Director's Dealing
2025-07-03 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 26, 2025, reporting the submission of matters to a vote of security holders at the company's 2025 Annual Meeting of Stockholders. It details the voting results for director elections, advisory approval of executive compensation, and ratification of the independent auditor appointment. This corresponds to an official announcement of voting results from a shareholder meeting, which fits the category 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is about 5031 characters, contains detailed vote counts, and is not a full annual report or other financial report. Therefore, the correct classification is DVA with high confidence.
2025-06-26 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-09 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.